Martin Austin
Chairman
Pharmaceutical Sciences
Zestagen
Switzerland
Biography
He has more than 35 years of senior executive experience from the pharmaceutical industry, including the position as Head of Business Development for the Pharmaceuticals Division at Hoffmann-La Roche, from the international investment community as a Principal at Paul Capital Partners Royalty Funds, a USA based specialist in Secondary Private Equity and Alternative Asset Investments, as well as from SME’s in the life sciences area. Areas of expertise include business analysis, business planning and competitive intelligence functions, M&A, equity investments, product divestments, and in- and out-licensing on a large international scale. Since 2005, Martin Austin has been Managing Director of TransformRx GmbH providing business advice to clients regarding investment and business development. He is the author of “Business Development for the Biotechnology and Pharmaceutical Industry” 2008 based on the courses he presents with CELforpharma (Brussels), Pharmaguys (Beijing), the World Intellectual Property Organisation of the United Nations and at Basel University as a part of the Masters in Drug Development Sciences degree course. Martin Austin is a Partner in MarraM Advisors sarl, an Investment and Fund Governance firm which is the sponsor of the BioIndustrial Finance Fund (in formation), and in Ventac Partners. Martin Austin also serves as a Board Member of RSA AG the Swiss subsidiary of the RSA Group.
Research Interest
Pharmaceutical Sciences
